{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:19:20Z","timestamp":1784089160107,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Medical Sciences"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.advms.2022.08.001","type":"journal-article","created":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T05:47:39Z","timestamp":1661665659000},"page":"311-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Renoprotective effects of dapagliflozin in an iron overload non-diabetic rat model"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9386-5879","authenticated-orcid":false,"given":"Sevde Nur","family":"F\u0131rat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eerife Mehlika","family":"Ku\u015fkonmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffer","family":"\u00c7aydere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"\u015eene\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema","family":"H\u00fcc\u00fcmeno\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cavit","family":"\u00c7ulha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.advms.2022.08.001_bib1","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s13300-018-0471-8","article-title":"SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice","volume":"95","author":"Wilding","year":"2018","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.advms.2022.08.001_bib2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.advms.2022.08.001_bib3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"492","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.advms.2022.08.001_bib4","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/14728222.2019.1624721","article-title":"Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies","volume":"23","author":"Warren","year":"2019","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.advms.2022.08.001_bib5","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-019-01148-3","article-title":"Dapagliflozin: a review in type 2 diabetes","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.advms.2022.08.001_bib6","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.advms.2022.08.001_bib7","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","article-title":"Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes and prior myocardial infarction: a sub-analysis from DECLARE TIMI-58 trial","volume":"139","author":"Furtado","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.advms.2022.08.001_bib8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12933-018-0790-0","article-title":"A\u00a0SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats","volume":"17","author":"Durak","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.advms.2022.08.001_bib9","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/10715760410001694044","article-title":"Oxidation of uric acid in rheumatoid arthritis: is allontoin a marker of oxidative stress?","volume":"38","author":"Yard\u0131m-Akayd\u0131n","year":"2004","journal-title":"Free Radic Res"},{"key":"10.1016\/j.advms.2022.08.001_bib10","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.5603\/KP.a2016.0085","article-title":"The relation of serum thiol levels and thiol\/disulfide homeostasis with the severity of coronary artery disease","volume":"74","author":"Altiparmak","year":"2016","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.advms.2022.08.001_bib11","doi-asserted-by":"crossref","first-page":"122e6","DOI":"10.1016\/S0361-090X(03)00029-1","article-title":"Daily variations of plasma malondialdehyde levels in patients with early breast cancer","volume":"27","author":"Akbulut","year":"2003","journal-title":"Cancer Detect Prev"},{"key":"10.1016\/j.advms.2022.08.001_bib12","doi-asserted-by":"crossref","first-page":"1563e74","DOI":"10.1016\/S0891-5849(03)00185-0","article-title":"Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications","volume":"34","author":"Martin-Gallan","year":"2003","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.advms.2022.08.001_bib13","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/S0891-5849(02)01167-X","article-title":"Oxidative stress in viral and alcoholic hepatitis","volume":"34","author":"Loguercio","year":"2003","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.advms.2022.08.001_bib14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.niox.2005.04.009","article-title":"Chronic iron overload enhances inducible nitric oxide synthase expression in rat liver","volume":"13","author":"Cornejo","year":"2005","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.advms.2022.08.001_bib15","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1093\/clinchem\/39.12.2522","article-title":"Optimized steps in fluorometric determination of thiobarbituric acid-reactive substances in serum: importance of extraction pH and influence of sample preservation and storage","volume":"39","author":"Wasowicz","year":"1993","journal-title":"Clin Chem"},{"key":"10.1016\/j.advms.2022.08.001_bib16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0003-2697(68)90092-4","article-title":"Estimation of total protein bound and non-protein sulphydryl groups in tissue with Ellman's reagen","volume":"25","author":"Sedlak","year":"1968","journal-title":"Anal Biochem"},{"key":"10.1016\/j.advms.2022.08.001_bib17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/aje\/kwm119","article-title":"Plazma fluorescent oxidation products as potential markers of oxidative stress for epidemiologic studies","volume":"165","author":"Wu","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.advms.2022.08.001_bib18","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.2353\/ajpath.2010.091071","article-title":"Adriamycin nephropathy: a failure of endothelial progenitor cell-induced repair","volume":"176","author":"Yasuda","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.advms.2022.08.001_bib19","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.lfs.2013.07.010","article-title":"Effects of asiaticoside on levels of podocyte cytoskeletal proteins and renal slit diaphragm proteins in adriamycin-induced rat nephropathy","volume":"93","author":"Wang","year":"2013","journal-title":"Life Sci"},{"key":"10.1016\/j.advms.2022.08.001_bib20","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"IgA nephropathy classification working group of the international IgA nephropathy network and the renal pathology society; conference participants","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.advms.2022.08.001_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.biopha.2018.03.176","article-title":"Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy","volume":"103","author":"Abdel-Wahab","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.advms.2022.08.001_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100777","article-title":"Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice","volume":"9","author":"Terami","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.advms.2022.08.001_bib23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/ijms19010137","article-title":"The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents renal and liver disease in western diet induced obesity mice","volume":"19","author":"Wang","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.advms.2022.08.001_bib24","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.gene.2019.05.009","article-title":"Potential protective effects of Dapagliflozin in gentamicin induced nephrotoxicity rat model via modulation of apoptosis associated miRNAs","volume":"707","author":"Mohamed","year":"2019","journal-title":"Gene"},{"key":"10.1016\/j.advms.2022.08.001_bib25","volume":"vol. 11","author":"Chang","year":"2016"},{"key":"10.1016\/j.advms.2022.08.001_bib26","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98720","article-title":"SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy","volume":"3","author":"Cassis","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.advms.2022.08.001_bib27","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1152\/ajprenal.00445.2017","article-title":"Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study","volume":"314","author":"Rajasekeran","year":"2018","journal-title":"Am J Physiol Ren Physiol"},{"issue":"4","key":"10.1016\/j.advms.2022.08.001_bib28","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1002\/jcp.26760","article-title":"Sodium-glucose cotransporter inhibitors and oxidative stress: an update","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J\u00a0Cell Physiol"},{"issue":"2","key":"10.1016\/j.advms.2022.08.001_bib29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","article-title":"Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation","volume":"117","author":"Kolijn","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.advms.2022.08.001_bib30","article-title":"Canagliflozin ameliorates renal oxidative stress and inflammation by stimulating AMPK-Akt-eNOS pathway in the isoprenaline-induced oxidative stress model","volume":"10","author":"Hasan","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.advms.2022.08.001_bib31","doi-asserted-by":"crossref","first-page":"865","DOI":"10.33594\/000000178","article-title":"Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor \u03b1-stimulated human coronary arterial endothelial cells","volume":"53","author":"Kerindongo","year":"2019","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.advms.2022.08.001_bib32","first-page":"213","article-title":"Effects of dapagliflozin in experimental sepsis model in rats","volume":"25","author":"Kingir","year":"2019","journal-title":"Ulus Travma Acil Cerrahi Derg"}],"container-title":["Advances in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S189611262200030X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S189611262200030X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:42:03Z","timestamp":1761824523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S189611262200030X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S189611262200030X"],"URL":"https:\/\/doi.org\/10.1016\/j.advms.2022.08.001","relation":{},"ISSN":["1896-1126"],"issn-type":[{"value":"1896-1126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renoprotective effects of dapagliflozin in an iron overload non-diabetic rat model","name":"articletitle","label":"Article Title"},{"value":"Advances in Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.advms.2022.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}